Quick Takeaways:
- ECO Animal Health has commercially launched Ecovaxxin MS, its poultry vaccine against Mycoplasma synoviae, across the European Union, marking the first product from the company’s proprietary R&D pipeline to reach the market.
- The vaccine is indicated for active immunization of future layer and breeder chickens from four weeks of age to reduce air-sac lesions, foot-pad lesions, and egg production losses caused by M. synoviae infections, which can lower egg production by 5–10% in affected flocks.
- ECO is leveraging its established EU commercial network and distribution partners to reach poultry markets representing over 220M layer birds annually, while advancing regulatory registrations for Ecovaxxin MS in the US, Latin America, and Asia.
Why It Matters?
ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning more than 220M layer birds annually and a vaccine aimed at reducing egg-production losses from Mycoplasma synoviae, the launch should support revenue growth, deepen customer relationships, and strengthen ECO’s credibility as a pipeline-led animal-health company.
Source: ECO Animal Health
